2020 - 02 - 11
News & Evens
2020 - 02 - 11
The first known case of novel (new) Coronavirus occurred on December 1st, 2019. On December 31, 2019, Chinese authorities notified the World Health Organization of multiple flu-like cases in Wuhan City, Hubei Province, China and which continues to expand is being closely monitored. On February 11, 2020, the World Health Organization named the disease Coronavirus disease 2019 (abbreviated “COVID-19”). Chinese health officials have reported tens of thousands of cases of COVID-19 in China, with the virus reportedly spreading rapidly from person-to-person in parts of that country. The United States reported the first confirmed instance of person-to-person with this virus on January 30, 2020. The U.S. government is working closely with public health partners, to respond to this public health threat. The public health’s goals are to detect quickly and minimize the introductions of this virus in the United States so as to reduce the spread and impact of this virus.
BiOptic, Inc. a Taiwan based R&D company with a branch office in La Canada Flintridge, California has developed a unique field-portable nucleic acid detection platform utilizing Direct-RT PCR / Direct- PCR + Capillary Gel Electrophoresis instrument (Qsep1) that can be utilized for rapid detection of the presence of the coronavirus (SARS-CoV-2). Combined with Qamp-mini (mini-PCR) and DirectGO we provide a rapid pathogen detection platform that eliminates the need for nucleic acid extraction. In addition, the Qsep Series capillary electrophoresis systems can be used in Next Generation Sequencing (NGS) labs for sample quality control, PCR product size, and concentration type analysis. For the detection of the presence of the coronavirus (SARS-CoV-2)., the epidemic prevention labs would need to select specific gene loci to develop primers, which then can be directly applied to BiOptic’s detection platform for rapid on-site testing of infectious diseases in mobile laboratories. By eliminating the need for nucleic acid extraction, the requirement for the number of instruments and overall testing time is greatly reduced. With a simplified pre-programmable mini-PCR instrument (Qamp mini), the clinical testing of the specimens can be performed by personnel, who have minimum training in molecular biology.
If there is an interest in reagent development companies or epidemic prevention centers to collaborate with BiOptic’s open platform please do not hesitate to contact: Mr. Varouj Amirkhanian (Cell: 818-679-4413), 1409 Foothill Blvd. La Canada Flintridge, CA 91011. absence.